We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Verona Pharma Plc | LSE:VRP | London | Ordinary Share | GB00BYW2KH80 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 55.00 | 45.00 | 65.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
14/2/2020 07:59 | All positive. Results The study took place between July 2017 and February 2018. Of 405 patients randomly assigned to medication, 375 (92.6%) completed the study. For peak FEV1 at Week 4, all four ensifentrine doses were superior to placebo (p ≤ 0.0001 Conclusions In this four-week Phase IIb study, all four ensifentrine doses significantly improved bronchodilation and symptoms, with a dose-ranging effect from 0.75 to 3 mg twice daily, and all doses well tolerated. The study supports the continuing development of ensifentrine in COPD. It's a long road but end in sight. | ewads | |
14/2/2020 07:39 | Wake wake news looks promising!! | joeblogg2 | |
12/2/2020 21:51 | Above average volume of 400k | matt123d | |
11/2/2020 11:04 | I've been buying a few the last few days - seems like there's a clear trend in the price. But Shore, in a note, pointed out: “Both Dr Zaccardelli and Mr Hahn bring significant experience, financial, operational and commercial, to lead Verona through its next phase of late-stage development. “Further with the senior management team based in the US we would anticipate a more active US capital markets strategy and see this as a positive. | ohisay | |
10/2/2020 22:18 | I'm waiting on trials coming up in a few months, made roughly 50% profit selling half my shares the day this was published: hxxps://ukinvestorma | dylanshares | |
10/2/2020 19:08 | The share price here never seems to make the running! It always waits and follows Verona movements on NASDAQ. Even this morning our share price should have matched Friday’s close on NASDAQ, but no, we waited, to ensure NASDAQ held the Friday close. When it did, we moved up. | bbonsall | |
10/2/2020 15:49 | Getting some volume through today, should be at least 65p | matt123d | |
10/2/2020 15:48 | Am only down £5k this time round as was hoping to recover part of my previous losses seeing this go to £1 but instead it has halved :( Hopefully some deals being lined up!!! | joeblogg2 | |
06/2/2020 17:16 | Added a few here today for a bounce | matt123d | |
03/2/2020 14:17 | Only 10 years...Directors have been milking us for years with promises that never materialised | pjm1162 | |
03/2/2020 10:38 | Buy when the Directors buy might be a good strategy from hereon in ! | ohisay | |
03/2/2020 09:26 | ...wouldnt be suprized. Ive been in VRP about 10 years and its always been jam tommorow. If these new changes were so good why dont we see a rise in the share price instaed of the usuual down? | haff1 | |
03/2/2020 09:03 | Placing on its way I wonder after the Management change ? | ohisay | |
29/1/2020 08:51 | Drip dripFun over here40's looming imo | pjm1162 | |
22/1/2020 14:37 | I spotted it months ago, and noticed Piers Morgan investing more, so I bought in when it was low. I sold half my stock just before the masses made it drop - partly due to article below, it was up 50% that day. hxxps://ukinvestorma Holding the other half for the upcoming studies/financial quarter. I think it's massively undervalued right now. | dylanshares | |
22/1/2020 14:04 | Such an unloved share. Volume is pitiful. | wageslave | |
21/1/2020 21:12 | over 11% up in the US - should have a good run upwards tomorrow! | sandy12345 | |
21/1/2020 16:07 | agree 100% bbanker, will accumulate as funds become available. | joeblogg2 | |
21/1/2020 15:46 | It’s a long way back but perhaps the market is beginning to understand that success with the research will be hugely welcome by the sufferers and will generate more interest in this stock that has little coverage from the pundits. I am a long term holder. | bbanker | |
21/1/2020 08:49 | some good reading there, on the way up! | sandy12345 | |
19/1/2020 18:12 | Consensus target price broker views seem to be around £3 per share FWIW. | ohisay | |
17/1/2020 18:01 | Who told you? | bbonsall |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions